- Home
- NMRA vs LCTX Comparison
NMRA vs LCTX Comparison
Compare NMRA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- LCTX
- Stock Information
- Founded
- NMRA 2019
- LCTX 1990
- Country
- NMRA United States
- LCTX United States
- Employees
- NMRA N/A
- LCTX N/A
- Industry
- NMRA
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMRA
- LCTX Health Care
- Exchange
- NMRA Nasdaq
- LCTX Nasdaq
- Market Cap
- NMRA 268.5M
- LCTX 274.0M
- IPO Year
- NMRA 2023
- LCTX N/A
- Fundamental
- Price
- NMRA $1.94
- LCTX $1.73
- Analyst Decision
- NMRA Hold
- LCTX Strong Buy
- Analyst Count
- NMRA 8
- LCTX 4
- Target Price
- NMRA $5.83
- LCTX $4.25
- AVG Volume (30 Days)
- NMRA 506.9K
- LCTX 1.9M
- Earning Date
- NMRA 11-11-2025
- LCTX 11-13-2025
- Dividend Yield
- NMRA N/A
- LCTX N/A
- EPS Growth
- NMRA N/A
- LCTX N/A
- EPS
- NMRA N/A
- LCTX N/A
- Revenue
- NMRA N/A
- LCTX $10,914,000.00
- Revenue This Year
- NMRA N/A
- LCTX N/A
- Revenue Next Year
- NMRA N/A
- LCTX $176.00
- P/E Ratio
- NMRA N/A
- LCTX N/A
- Revenue Growth
- NMRA N/A
- LCTX 76.43
- 52 Week Low
- NMRA $0.61
- LCTX $0.37
- 52 Week High
- NMRA $17.19
- LCTX $1.83
- Technical
- Relative Strength Index (RSI)
- NMRA 58.78
- LCTX 69.14
- Support Level
- NMRA $1.70
- LCTX $1.64
- Resistance Level
- NMRA $1.93
- LCTX $1.77
- Average True Range (ATR)
- NMRA 0.13
- LCTX 0.11
- MACD
- NMRA 0.01
- LCTX -0.00
- Stochastic Oscillator
- NMRA 82.05
- LCTX 75.00
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.